Market Overview

Why Forte Biosciences's Stock Is Trading Higher Today


Forte Biosciences (NASDAQ: FBRX) shares are trading higher on Friday after getting two upgrades.

Chardan Capital upgraded the stock from Neutral to Buy and announced a price target of $45 per share. In addition, Brookline Capital initiates coverage with a Buy rating and $90 price target.

Forte Biosciences is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2 a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial in mid-2020.

Forte Biosciences's stock traded up 8.88% at $29.06 per share at the time of publication on Friday. The stock has a 52-week high of $66.75 and a 52-week low of $6.33.

Latest Ratings for FBRX

Sep 2020Chardan CapitalMaintainsBuy
Sep 2020Chardan CapitalMaintainsBuy
Aug 2020Brookline CapitalInitiates Coverage OnBuy

View More Analyst Ratings for FBRX
View the Latest Analyst Ratings


Related Articles (FBRX)

View Comments and Join the Discussion!

Posted-In: why it's movingUpgrades Price Target Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at